Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3317-3329

  Zhang, Xinliang ^a   Dong, Shimin ^a   Qin, Yanjun ^a   Bian, Xiaohua ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Erythropoietin; Myocardial injury; Sepsis

Indexed keywords

CEFTRIAXONE; CREATINE KINASE; ERYTHROPOIETIN; I KAPPA B; AUTACOID; BIOLOGICAL MARKER; CARDIOTONIC AGENT; CYTOKINE; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; FLOW CYTOMETRY; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE; HEART MUSCLE INJURY; HEART PROTECTION; HISTOPATHOLOGY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MORTALITY; MOUSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; SEPSIS; ANIMAL; CARDIOMYOPATHIES; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; TIME FACTOR;

MUS; RATTUS;

ANIMALS; APOPTOSIS; BIOMARKERS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HEMODYNAMICS; INFLAMMATION MEDIATORS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MORTALITY; RATS; SEPSIS; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84922326732     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3155     Document Type: Article

References (29)

1. Levy MM, Fink MP, Marshall JC, et al; International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29: 530-538, 2003.
2. Shimaoka M and Park EJ: Advances in understanding sepsis. Eur J Anaesthesiol Suppl 42: 146-153, 2008.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J and Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310, 2001.
4. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32: 858-873, 2004.
5. Meziani F, Tesse A and Andriantsitohaina R: Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol Rep 60: 75-84, 2008.
6. Tetta C, Fonsato V, Ronco C and Camussi G: Recent insights into the pathogenesis of severe sepsis. Crit Care Resusc 7: 32-39, 2005.
7. Silva E, Passos Rda H, Ferri MB and de Figueiredo LF: Sepsis: from bench to bedside. Clinics (Sao Paulo) 63: 109-120, 2008.
8. Cinel I and Dellinger RP: Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 20: 345-352, 2007.
9. Tramontano AF, Muniyappa R, Black AD, et al: Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308: 990-994, 2003.
10. Maiese K, Li F and Chong ZZ: Erythropoietin in the brain: can the promise protect be fulfilled? Trends Pharmacol Sci 25: 577-583, 2004.
11. Juul SE, Yachnis AT and Chistensen RD: Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52: 235-249, 1998.
12. Cai Z, Manalo DJ, Wei G, et al: Hearts from rodents exposed to intermittent hypoxia orerythropoietin are protected against ischemia-reperfusion injury. Circulatio 108: 79-85, 2003.
13. Aoshiba K, Onizawa S, Tsuji T and Nagai A: Therapeutic effects of erythropoietin in murine models ofendotoxin shock. Crit Care Med 37: 889-898, 2009.
14. Bemardi P, Scorrano L, Colonna R, Petronilli V and Di Lisa F: Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem 264: 687-701, 1999.
15. Tan C, Dlugosz PJ, Peng J, et al: Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by BCL-2. J Biol Chem 281: 14764-14775, 2006.
16. Germ DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
17. Nechushtan A, Smith CL, Lamensdorf I, Yoon SH and Youle RJ: Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 153: 1265-1276, 2001.
18. Dschietzig T, Richter C, Pfannenschmidt G, et al: Dexamethasone inhibits stimulation of pulmonary endothelins by proinflammatory cytokines: possible involvement of a nuclear factor kappa B dependent mechanism. Intensive Care Med 27: 751-756, 2001.
19. Yinjun L, Jie J and Yungui W: Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk Res 29: 99-105, 2005.
20. Wichterman KA, Baue AE and Chaudry IH: Sepsis and septic shock-A review of laboratory models and a proposal. J Surg Res 29: 189-201, 1980.
21. Telford WG, King LE and Fraker PJ: Comparative evaluation of several DNA binding dyes in the detection of apoptosia-associated chromatin degradation by flow cytometry. Cytometry 13: 137-143, 1992.
22. Gurkan F, Alkaya A, Ece A, et al: Cardiac troponin-I as a marker of myocardial dysfunction in children with septic shock. Swiss Med Wkly 134: 593-596, 2004.
23. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP and Gorus FK: Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 46: 650-657, 2000.
24. Turner A, Tsamitros M and Bellomo R: Myocardial cell injury in septic shock. Crit Care Med 27: 1775-1780, 1999.
25. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998.
26. Phrommintikul A, Haas SJ, Elsik M and Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369: 381-388, 2007.
27. Zarychanski R, Turgeon AF, McIntyre L and Fergusson DA: Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 177: 725-734, 2007.
28. Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141: 14-31, 2008.
29. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3: CD003407, 2006.